Javier Ignacio Muñoz González-rekin lankidetzan egindako argitalpenak (19)

2024

  1. Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 79, Núm. 3, pp. 711-723

2023

  1. Bone and Cytokine Markers Associated With Bone Disease in Systemic Mastocytosis

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 5, pp. 1536-1547

  2. Mast Cell Activation Syndromes: Comparison Between Two Scoring Models to Predict for Mast Cell Clonality

    The journal of allergy and clinical immunology. In practice, Vol. 11, Núm. 3, pp. 908-919

2022

  1. Altered innate immune profile in blood of systemic mastocytosis patients

    Clinical and Translational Allergy, Vol. 12, Núm. 6

  2. Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis

    Cancers, Vol. 14, Núm. 10

  3. Frequency and prognostic impact of blood-circulating tumor mast cells in mastocytosis

    Blood, Vol. 139, Núm. 4, pp. 572-583

2021

  1. Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis

    American Journal of Human Genetics, Vol. 108, Núm. 2, pp. 284-294

  2. Pathogenic and diagnostic relevance of KIT in primary mast cell activation disorders

    Annals of Allergy, Asthma and Immunology, Vol. 127, Núm. 4, pp. 427-434

  3. Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study

    The Lancet Haematology, Vol. 8, Núm. 3, pp. e194-e204

  4. Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal

    HemaSphere, Vol. 5, Núm. 11, pp. E646

2019

  1. Bone marrow mast cell antibody-targetable cell surface protein expression profiles in systemic mastocytosis

    International Journal of Molecular Sciences, Vol. 20, Núm. 3

  2. Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis

    Blood, Vol. 134, Núm. 5, pp. 456-468

  3. Mars: Mutation-adjusted risk score for advanced systemic mastocytosis

    Journal of Clinical Oncology, Vol. 37, Núm. 31, pp. 2846-2856

2018

  1. Characterization of CD34 + hematopoietic cells in systemic mastocytosis: Potential role in disease dissemination

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 73, Núm. 6, pp. 1294-1304

  2. Impact of somatic and germline mutations on the outcome of systemic mastocytosis

    Blood Advances, Vol. 2, Núm. 21, pp. 2814-2828

2017

  1. Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature

    Oncotarget, Vol. 8, Núm. 40, pp. 68950-68963

2016

  1. Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression

    Leukemia, Vol. 30, Núm. 1, pp. 124-130

  2. KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression

    Blood, Vol. 127, Núm. 6, pp. 761-768

2015

  1. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: Diagnostic implications

    Modern Pathology, Vol. 28, Núm. 8, pp. 1138-1149